Adagio Therapeutics Inc. (NASDAQ: ADGI) Announces That ADG20 Produced A Neutralizing Response Against The Omicron Variant

Adagio Therapeutics Inc. (NASDAQ: ADGI) has summarised recent findings that were published in three different publications showing its flagship monoclonal antibody (mAb), ADG20, had a neutralizing effect against the Omicron variant of COVID-19. In addition, the company also outlined various initiatives addressing the present and future variants of SARS-CoV-2. 

ADG20 evaluated as treatment and prevention of COVID-19

In its worldwide Phase 2/3 clinical trials, Adagio is exploring ADG20 for both the treatment and prevention of COVID-19. In addition, Adagio is in talks with the US Food and Drug Administration (FDA) about possible protocol changes in its worldwide Phase 2/3 clinical studies, including a higher dose of ADG20 for the treatment and prevention of COVID-19 caused by the Omicron variation.

The recently published in vitro trials looked at the neutralization ability of larger mAbs panels against the Omicron strain in pseudovirus and authentic assays. ADG20 is one of only a few mAbs in late-stage clinical testing or with Emergency Use Authorization that displayed neutralizing activity against Omicron, according to findings from all three studies. Furthermore, the data demonstrate that ADG20 has an IC50, a measure of neutralization potency, of roughly 0.4 to 1.1 g/mL in two different legitimate neutralization assays against Omicron, comparable to AZD7742 and sotrovimab.

Adagio co-founder and chief scientific officer Laura Walker said, “What is critical to assessing the potential clinical effectiveness of SARS-CoV-2 mAbs is the neutralization potency by the mAb against a specific variant. While findings may show that ADG20 has reduced potency against Omicron when compared to its high potency against all other variants of concern, including Delta, the data support that ADG20 is among the few mAbs to demonstrate neutralizing activity against the Omicron variant and warrants its continued development.”

There is a need for multiple preventive solutions against COVID-19

CEO and co-founder of Adagio Tillman Gerngross said, “It is abundantly clear that no single product will fully address the evolving nature of the COVID-19 pandemic, and that multiple preventative and therapeutic solutions are needed. Based on both in-house data and third-party findings, we are confident that ADG20 can be an important tool in the fight against this virus.”